The accuracies of the endocrine profiles scores (classical CAH: 95%, non-classical CAH: 91%) reflected that these were better markers of treatment efficacy than the best individual biochemical marker (FSH: 71%). This evidence concerns the gene BRD2 and congenital adrenal hyperplasia.